AOA Dx, Inc

AOA will revolutionize early-stage diagnosis of ovarian cancer by developing AKRIVIS GD, an accurate liquid biopsy that detects gangliosides which are specific to cancer.

Operating in health based in Denver, CO, USA; Cambridge, MA, USA, AOA Dx, Inc operates.

Profile

AOA Dx is developing the next frontier in early-stage cancer detection for women through our pioneering work in glycolipids and proprietary biomarker technology.

Within the health space, the company focuses on its core offering rather than a broad product line.

The business is associated with Denver, CO, USA; Cambridge, MA, USA.

Its current recorded stage is Summer 2021.

Recorded headcount: 25 employees.

Website: www.aoadx.com